Medipharm Labs Sees CEO Pat McCutcheon Step Down From Role, Remain As Chairman

Medipharm Labs (TSX: LABS) this morning announced drastic changes to its leadership role, with the major change being that CEO Pat McCutcheon will be stepping down from his role as CEO, with no permanent replacement named. The result will be that the company will have both an interim CFO and an interim CEO helming the company.

The leadership changes announced this morning are reportedly to “prepare the company for its next phase of growth,” while also focusing on that of efficiency and cost savings. Taking McCutcheon’s role on an interim basis will be that of Keith Stratchan. McCutcheon meanwhile will be remaining with the company in the role of Chairman of the board.

Also outlined this morning is that Warren Everitt will remain as CEO of the Asia Pacific region for the company, while Olga Utkutug has been named as the interim CFO of the company, effective December 8, 2020. The company has yet to find a permanent replacement since Bobby Kwon resigned from the company, effective at the end of November.

The company is said to immediately begin the process of finding a permanent CEO replacement, while that process is already underway for the role of CFO.

Medipharm Labs last traded at $0.55 on the TSX.


.Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Copper Juniors Could Explode After This Trade War Move | Christian Easterday – Hot Chili

Silver Is Rarer Than Gold, And the Market’s Waking Up | Shawn Khunkhun – Dolly Varden Silver

Gold Will Hit North of $4,000: Who’s Actually Producing? | Shane Williams – West Red Lake

Recommended

ESGold Sees ANT Survey Reveal Vertically Continuous System To 1,200 Metres Depth

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Related News

Medipharm Labs Reports Revenues of $31 million for Second Quarter

Medipharm Labs (TSX: LABS) filed its second quarter earnings after the bell this evening, reporting...

Monday, August 12, 2019, 05:35:41 PM

Hexo Has Filed A $35 Million Counterclaim Against Medipharm Labs

It appears that Hexo Corp (TSX: HEXO) (NYSE: HEXO) has filed a counterclaim against Medipharm...

Thursday, June 18, 2020, 11:48:39 AM

Medipharm Labs Expands Facility Threefold, Introduces New Automated Processes

Medipharm Labs (TSX: LABS) has received Health Canada licensing for its newly expanded production facility...

Monday, December 30, 2019, 08:25:07 AM

Is The Medipharm Labs Supply Arrangement The Source Of Cronos’ Late Filings?

Earlier this week, Cronos Group (TSX: CRON) (NASDAQ: CRON) quietly announced that they would delay...

Wednesday, March 4, 2020, 12:12:37 PM

MediPharm Labs Revenues Increase 37.8% to $43.38 Million

Medipharm Labs (TSX: LABS) announced third quarter earnings this morning, posting revenues of $43.38 million...

Tuesday, November 12, 2019, 08:44:55 AM